Moleculin Biotech, a U.S. clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, announced that it has entered into an agreement to expand production capability for Annamycin.
Moleculin has engaged BSP Pharmaceuticals (Italy) to begin preparations for commercial scale production of Annamycin drug product.
Clinical stage drugs developed by Moleculin are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. Company also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
Based in Latina Scalo, Italy, BSP Pharmaceuticals develops and manufactures anticancer drugs. The company produces small molecule products and drugs, such as proteasome inhibitors, ADCs (conjugation and fill/finishing), and lipid-based formulations (nano and micro-emulsions, and liposomal formulations), as well as ADC drug products. It offers oral solid and sterile injectable formulations development, compatibility studies, and cleanibility studies; formulations and process development services for conventional dosage forms; analytical methods development and validation; clinical supply services; and commercial supply services.